Mirum Pharmaceuticals Oma pääoma 2025

Mitä Mirum Pharmaceuticals tekee?

Mirum Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and marketing of therapeutics for rare intestinal diseases. The company was founded in 2018 in California, USA and has experienced rapid growth since then. The company was founded after an unusual event in 2015 when Shire Pharmaceuticals plc, a large British pharmaceutical company, acquired the biotech company Lumena Pharmaceuticals Inc. The management of Lumena discovered a compound that they believed could relieve cholestasis, a condition where bile cannot flow adequately and therefore remains in the liver. They realized that this compound, if modified and used in a new formulation, could also be used to treat other rare intestinal diseases. The management of Lumena decided to pursue this idea and thus founded Mirum Pharmaceuticals Inc. The company's business model is to develop novel medications for the treatment of severe and rare intestinal diseases through a combination of in-house research and external collaborations. Mirum Pharmaceuticals Inc aims to fill a niche focusing on smaller patient populations that are often overlooked by larger pharmaceutical companies due to their rarity. The company also aims to work closely with patients and their families to ensure that their needs and concerns are incorporated into their product development processes. Currently, Mirum Pharmaceuticals Inc's research and development efforts focus on two main areas: cholestasis and intestinal enteropathies. Cholestasis is a condition where the liver is unable to secrete bile into the intestine, resulting in the accumulation of bile in the body and damage to liver cells and other organs. Mirum Pharmaceuticals Inc is currently developing Maralixibat, a medication targeting the treatment of intrahepatic cholestasis in children. Intestinal enteropathies are rare intestinal diseases characterized by a disruption of the intestinal tract. Mirum Pharmaceuticals Inc is dedicated to researching and developing a medication for the treatment of PFIC, a rare condition where bile fluid is no longer adequately excreted. In this regard, the company has entered into an agreement with Dova Pharmaceuticals Inc., which was acquired by Merck&Co. in mid-2019. Under this agreement, Mirum Pharmaceuticals Inc acquired the rights to a medication for the treatment of PFIC developed by Dova. Mirum Pharmaceuticals solutions aim to treat patients on a relevant basis and provide support for families and caregivers of patients. In summary, Mirum Pharmaceuticals Inc is a biopharmaceutical company that emerged from a spin-out of Lumena Pharmaceuticals Inc from Shire. It has focused on the development of therapeutics for rare intestinal diseases and works closely with patients and their families to ensure their concerns are considered in product development processes. The product research of Mirum Pharmaceuticals Inc currently focuses on Maralixibat, a medication for the treatment of intrahepatic cholestasis, as well as Mirum Pharmaceuticals Inc, a medication for the treatment of PFIC. Mirum Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.